Provider review
Goldspan Health Review: A 29-Product Catalog, and the Page That Names the Wrong Drug
Goldspan sells a 29-product catalog through a storefront it does not operate, under hedged language that never quite promises anything. We loaded every one of those 29 pages rather than sampling, because each product link on the catalog is labeled only "Rx" and there is no honest way to guess. The sweep turned up the thing worth knowing: the tirzepatide sublingual microdose page, in the section headed "What's in your plan", says a buyer receives compounded sublingual semaglutide.
A hedged 29-product catalog run through somebody else's storefront, with a tirzepatide page that tells buyers they are getting semaglutide.
Worth trusting if
- You want prices before an account, because all 29 are visible without signing in
- You are buying the GHK-Cu cream, whose claim is nearly within its evidence and which says the word "compounded"
- You want the clinicians named, which the storefront does
Be skeptical if
- You are buying the tirzepatide sublingual microdose, whose own plan description names semaglutide
- You want to know which pharmacy makes your prescription, because no page names one
- You need a needle-free GLP-1 that has been shown to be absorbed, because no trial has tested this route
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens goldspanhealth.com. A link is not a recommendation to take anything.
Provenance
What Goldspan Health actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Tirzepatide Sublingual Microdose — $199 per 28 days; the full-dose sublingual is $299.
- Sermorelin (Injection) — $174 per 28 days.
- NAD+ (Injection) — $199 per 28 days.
- PT-141 (Injection) — $245 per 28 days, the dearest item in the catalog after the tirzepatide injectables.
- GHK-Cu (Topical, Cream) 0.5% — $149 per 28 days.
- Glutathione (Injection) — $149 per 28 days, the same figure as the GHK-Cu cream.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Molecules with human evidence
For the use they are sold for, out of 6 products reviewed here. The evidence belongs to the molecule, not to Goldspan Health.
3
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Goldspan Health’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Tirzepatide Sublingual MicrodoseTirzepatide · Compounded (503A)No trial supports this claim
“A daily, needle-free dual GIP/GLP-1 microdose that dissolves under the tongue and may help curb appetite, quiet cravings, and support metabolic balance. Monthly dose.”
Read on the Goldspan Health site, September 2026
No trial for this use
What the trials show for Tirzepatide
As of September 2026, no registered trial has tested tirzepatide sublingually. Checked on 2026-09-01 against the ClinicalTrials.gov v2 API with no status filter: "sublingual tirzepatide" returns zero studies, "tirzepatide sublingual" zero, and "oral tirzepatide" zero. A bare "tirzepatide" search in the same pass returns 278 records, so the zeros are a finding rather than a broken search. Every trial in the tirzepatide program, SURMOUNT-1 included, gave a once-weekly SUBCUTANEOUS INJECTION. Tirzepatide is a 39-amino-acid peptide, and peptides that size are the standard example of poor mucosal absorption; the one oral GLP-1 that reached approval needed a dedicated absorption enhancer and its own phase 3 program to establish that anything arrived. Nothing equivalent exists for tirzepatide by any non-injected route, and Goldspan publishes no bioavailability figure.
The molecule has one of the strongest trial records in medicine and none of it was collected by this route. Every outcome named — curbing appetite, quieting cravings, metabolic balance — comes from a weekly injection, and no study has established that a daily dose under the tongue delivers a measurable amount of a 39-amino-acid peptide at all. This is also the page whose "What's in your plan" section says a buyer receives compounded sublingual SEMAGLUTIDE. A reader cannot resolve which drug the page is describing.1
Sermorelin (Injection)Sermorelin · Compounded (503A)No trial supports this claim
“A nightly peptide injection that may help support energy, sleep, recovery, and lean body composition. Monthly dose.”
Read on the Goldspan Health site, September 2026
No trial for this use
What the trials show for Sermorelin
As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returned 19 records, the most recent published in 2005. Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None tests energy, sleep, recovery or body composition in healthy adults. A parallel ClinicalTrials.gov search returned 27 studies; the two closest to the marketed use are both phase 2 and both terminated, at 13 and 5 participants.
Four outcomes and no mechanism. This is a shorter sentence than most sellers write and it is emptier, because it drops the one true thing that can be said about sermorelin — that it stimulates growth hormone release, which is what all nineteen randomized trials measured — and keeps only the four things none of them measured.2
NAD+ (Injection)NAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)No trial supports this claim
“A weekly injection of a coenzyme involved in cellular energy that may help support mental clarity, focus, and healthy aging. Monthly dose.”
Read on the Goldspan Health site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search for injected NAD+ in humans returns no completed randomized trial supporting a restoration-of-function claim, and a PubMed search for nicotinamide adenine dinucleotide combined with injection or subcutaneous, filtered to the randomized-controlled-trial publication type, returns zero records. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
"A coenzyme involved in cellular energy" is correct and is a fact about biochemistry, not about the injection. Mental clarity, focus and healthy aging are three outcomes with no completed randomized trial of injected NAD+ behind any of them. Note what "healthy aging" does as the third item: it is the only one of the three that could never be shown to have failed.3
PT-141 (Injection)Bremelanotide (PT-141) · Compounded (503A)Claim reaches past the trials
“An on-demand peptide injection that may help support sexual desire and arousal through brain pathways. Monthly supply.”
Read on the Goldspan Health site, September 2026
Phase 3 trials
What the trials show for Bremelanotide (PT-141)
- NCT02333071 RECONNECT Study 1 — Phase 3, completed, n=723. Premenopausal women with hypoactive sexual desire disorder. One of the two trials behind the FDA approval of bremelanotide.
- NCT02338960 RECONNECT Study 2 — Phase 3, completed, n=714. The identical second trial, in the same population.
Almost everything in this sentence is right, and what is missing is who it was right for. "On-demand" is the correct dosing pattern, "through brain pathways" is the correct mechanism — bremelanotide acts centrally on melanocortin receptors, not on blood flow — and desire and arousal are exactly what RECONNECT 1 and 2 measured across 1,437 participants. Those participants were all premenopausal women with hypoactive sexual desire disorder. Goldspan's sentence names no population at all, on a page any buyer can order from, and never mentions that an approved version of this molecule exists.4
GHK-Cu (Topical, Cream) 0.5%GHK-Cu · Compounded (503A)Claim reaches past the trials
“A compounded face cream with copper peptide that may help support skin texture and firmness. Monthly supply.”
Read on the Goldspan Health site, September 2026
Phase 2 only
What the trials show for GHK-Cu
- NCT07437586 — Phase 2, recruiting, n=60. Acute skin wound healing, recruiting. The completed GHK-Cu registry record is a 27-participant phase 4 study of facial skin quality, hydration and barrier function — a topical application, like this product.
This is the closest Goldspan comes to a supportable claim, and it reaches past the evidence by one word. The route is topical and the site is facial skin, which is the whole of what the GHK-Cu literature covers, and "texture" sits inside the skin-quality outcome the 27-participant study measured. "Firmness" does not — it is a mechanical property nobody measured in that record. The word to notice is that the sentence also says "compounded", which is more disclosure than most GHK-Cu sellers offer.5
Glutathione (Injection)Glutathione · Compounded (503A)No trial supports this claim
“A twice weekly injection of a naturally occurring antioxidant that may help support detoxification, immune function, and skin health. Monthly dose.”
Read on the Goldspan Health site, September 2026
No trial for this use
What the trials show for Glutathione
As of August 2026, a PubMed search for glutathione in title or abstract, combined with an injected route and with skin, detoxification, fatigue or energy, restricted to the randomized-controlled-trial publication type, returned seven records. Not one tests injected glutathione on its own for any of those outcomes. On ClinicalTrials.gov, 268 studies list glutathione as an intervention; restricting to injected routes returns three, in mantle-cell lymphoma, acute liver failure and pneumonia.
"A naturally occurring antioxidant" is true and is a description of the molecule rather than a claim about the injection. Detoxification, immune function and skin health each have no randomized trial of injected glutathione behind them. The product page then expands the three into five, adding "antioxidant support" and "overall resilience" under a heading that reads, in full, "May support".6
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named anywhere on either domain. Goldspan states a class and stops: "All therapies are dispensed by a pharmacy licensed under U.S. FDA §503A or §503B", and each of the 29 product pages says only "prepared by a state-licensed pharmacy". Naming both 503A and 503B as alternatives leaves a buyer unable to tell which set of rules applies to what arrives — a 503A preparation is made for one named patient by a state-licensed pharmacy, while a 503B product comes from an outsourcing facility registered with FDA and subject to CGMP. Because no pharmacy is named, none could be screened against the FDA warning-letter index. What IS named is the platform: the storefront at altroapp.com belongs to Altro Health (Lyv Health, Inc.), 169 Madison Ave, New York, and three clinicians are named there — Dr. Hinds as medical director, with Dr. Butte and Dr. Morse as clinical advisers. The medical group itself appears only as "affiliated professional medical group", and Goldspan's own legal entity, address and governing law appear nowhere.
Read on the Goldspan Health site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency, purity or sterility result is published for any of the 29 products. The nearest thing to a quality statement is the class designation — "licensed under U.S. FDA §503A or §503B" — which describes a regulatory category rather than a test, and note that registration under 503B is not an approval and confers no quality finding on any product. The LegitScript seal displayed in this chain is real: certificate 51596535 resolves, while an invented certificate id returns 403 through the same request. It certifies www.altroapp.com, the storefront, and goldspanhealth.com makes no LegitScript claim of its own.
Read on the Goldspan Health site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
goldspanhealth.com says "IN 50 STATES" and "AVAILABLE IN 50 STATES", and the storefront says "Available in all 50 states and Washington, D.C." Its own Terms §3 then says "Some therapies are unavailable in certain states or based on medical history", and no page publishes a list of which therapies or which states. Both statements can be true at once — the service reaches everywhere, individual products may not — and a buyer has no way to find out which applies to the product they are about to order.
Read the full licensing claim
Three clinicians are named on the storefront: Dr. Hinds (medical director), Dr. Butte (clinical adviser, internal medicine) and Dr. Morse (clinical adviser, OB-GYN and menopause), all attributed to Altro Health. The prescribing medical group is described only as an "affiliated professional medical group" and is not named. No state license number is published, and Goldspan publishes no legal entity of its own.
Read on the Goldspan Health site, September 2026.
Regulatory
The FDA warning letter
Checked, and none found
Assessment
What holds up, and what does not
- Every one of the 29 products shows its price and its billing period before any account, questionnaire or intake.
- Its GHK-Cu cream describes itself as compounded, which most sellers of that molecule do not.
- Three clinicians are named with roles and specialties, and a medical director is identified.
Show 4 more
- Its claims are hedged rather than asserted, which is more careful language than much of this category uses.
- Its PT-141 page gets the mechanism right — central brain pathways, not blood flow — where sellers routinely get it wrong.
- Its LegitScript certificate is genuine and resolves; an invented certificate id returns 403 through the same request.
- No FDA warning letter against Goldspan, Altro Health or Lyv Health.
- The tirzepatide sublingual microdose page, under "What's in your plan", says the buyer receives compounded sublingual semaglutide.
- No pharmacy is named on either domain — only the class, "§503A or §503B", which are two different sets of rules.
- Goldspan publishes no legal entity, no address and no governing law; the only identifiable operator is the storefront's.
Show 5 more
- The LegitScript certification belongs to altroapp.com, the storefront, not to goldspanhealth.com.
- "IN 50 STATES" on the homepage against "Some therapies are unavailable in certain states" in its own terms, with no list either way.
- Four of its six peptide claims name outcomes with no trial behind them at all.
- "Pause, delay, or cancel your subscription at any time" on every product page against a refund policy reading "all sales are final".
- Billing runs every 28 days, which is thirteen charges a year rather than twelve, while the price is displayed as "/month".
Verdict
The bottom line
If you are buying the tirzepatide sublingual microdose, read the "What's in your plan" box first — it names semaglutide, and you should get that resolved in writing before you pay. Everything else here is a competent white-label storefront with careful hedged language over mostly untested outcomes, priced openly, dispensed by a pharmacy it will not name.
Opens goldspanhealth.com. A link is not a recommendation to take anything.
We loaded all 29 pages, and here is why
Goldspan's catalog gives every product the same link text: "Rx", pointing at an opaque UUID. There is no product name in the URL, no ordering, no category in the path. Sampling that catalog would not have been sampling — it would have been guessing.
So all 29 pages were loaded and their text captured. Every count and every quotation on this page comes out of that sweep.
The single most useful thing it found is on one page.
Full analysis — 4 more sectionsThe page that names the wrong drug · The house voice · What the catalog does not say · The 28-day month
The page that names the wrong drug
On the Tirzepatide Sublingual Microdose page, under the heading "What's in your plan":
"Compounded sublingual semaglutide microdose, prepared by a state-licensed pharmacy."
That is the section that tells a buyer what will arrive. It names a different molecule from the one in the product title, in the hero description, and in the section directly beneath it headed "WHY TIRZEPATIDE SUBLINGUAL MICRODOSE".
We are not saying anything about what a pharmacy actually ships — nobody outside the company can see that, and this is not evidence about it. What we can say is that the page a buyer reads before paying for it contains two different drug names for the same product, and a buyer has no way to tell which one governs.
The house voice
All 29 descriptions are hedged the same way:
Sermorelin — "may help support energy, sleep, recovery, and lean body composition."
NAD+ — "may help support mental clarity, focus, and healthy aging."
Glutathione — "may help support detoxification, immune function, and skin health."
That is more careful than the flat assertions elsewhere in this category, and it is worth crediting. It also changes nothing about the searches, which return the same thing whether the verb is hedged or not.
Watch what the third item in each list is doing. Energy, mental clarity and immune function are at least the kind of thing a trial could measure. "Healthy aging" and "overall resilience" — the latter from the glutathione page's benefits panel — are the kind of thing that could never be shown to have failed.
What the catalog does not say
No pharmacy. Not on goldspanhealth.com, not on the storefront, not on any of the 29 product pages. The site states a class: "licensed under U.S. FDA §503A or §503B". Those are not two flavors of the same thing — 503A is a state-licensed pharmacy compounding for one named patient, 503B is a registered outsourcing facility working under CGMP — and offering both as alternatives tells a buyer nothing about which applies.
No entity. goldspanhealth.com carries no LLC, no Inc., no address and no governing law. The only identifiable operator in the chain is Lyv Health, Inc., which owns the storefront.
No test results. No certificate of analysis, no potency figure, no purity figure, for any of the 29.
The 28-day month
Each product shows a price with "/month" beside it. The plan card underneath says "Billed every 28 days", and the order timeline says "Every 4 weeks — Your order renews".
Twenty-eight days is not a month. It is thirteen charges a year, not twelve.
Questions
Frequently asked questions
Which drug does the tirzepatide sublingual microdose actually contain?
The page does not settle it. Its title, its hero description and its "WHY" section all say tirzepatide; its "What's in your plan" section says "Compounded sublingual semaglutide microdose". That is an error on a live page, and it is not evidence about what any pharmacy ships — which nobody outside the company can see. Get it resolved in writing before paying.
Is a sublingual GLP-1 absorbed?
Nobody has published an answer for tirzepatide, and Goldspan offers none. Searched with no status filter, ClinicalTrials.gov returns zero studies for sublingual tirzepatide against 278 for tirzepatide overall in the same pass. Every trial in the program used a weekly subcutaneous injection. Tirzepatide is a 39-amino-acid peptide, and the one oral GLP-1 that reached approval needed a dedicated absorption enhancer and its own phase 3 program to establish that anything arrived.
Which pharmacy compounds these?
No page names one. The site says only that therapies are dispensed by a pharmacy "licensed under U.S. FDA §503A or §503B", which names a category rather than a company. Because no pharmacy is named, none could be screened against the FDA warning-letter index.
Is the LegitScript seal real?
Yes, and it belongs to the storefront. Certificate 51596535 resolves, while an invented certificate id returns 403 through the same request — so this is a genuine certification rather than a decorative badge. It certifies www.altroapp.com. goldspanhealth.com makes no LegitScript claim of its own.
Does Goldspan hold an FDA warning letter?
No FDA warning letter. We searched FDA's warning-letter database on September 1, 2026 for "Goldspan", "Goldspan Health", "Altro Health", "Altro" and "Lyv Health", and every one came back empty. No pharmacy is named anywhere on either domain, so no pharmacy could be searched for.
Is it really available in all 50 states?
The homepage says so twice and the storefront agrees. Its own Terms §3 then says "Some therapies are unavailable in certain states or based on medical history", and no page lists which therapies or which states. Both can be true — the service reaches everywhere, individual products may not — and a buyer cannot find out which applies to what they are ordering.
Glossary
Key terms
Show definitions
- Sublingual
- Administered under the tongue for absorption through the oral mucosa. Peptides absorb poorly this way, which is why the one approved oral GLP-1 tablet uses an absorption enhancer and a fasting protocol rather than mucosal absorption.
- White-label storefront
- A commerce platform operated by one company and presented under another company's brand. Here the brand is Goldspan Health and the platform is Altro Health, whose terms, certification and named clinicians govern the transaction.
Compare
Others selling what Goldspan Health sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Goldspan Health's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 6 sources
- US National Library of Medicine (2026). ClinicalTrials.gov v2 API, no status filter: "sublingual tirzepatide" 0 studies, "tirzepatide sublingual" 0, "oral tirzepatide" 0; control "tirzepatide" 278 records in the same pass. ClinicalTrials.gov. https://clinicaltrials.gov/search?intr=tirzepatide
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] — 19 records, most recent 2005; ClinicalTrials.gov intervention "sermorelin" — 27 studies. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). PubMed search: nicotinamide adenine dinucleotide AND (injection OR subcutaneous) AND randomized controlled trial[pt] — zero records for injected NAD+ in humans. PubMed. https://pubmed.ncbi.nlm.nih.gov/?term=nicotinamide+adenine+dinucleotide+AND+injection+AND+randomized+controlled+trial%5Bpt%5D
- Kingsberg SA, Clayton AH, Portman D, et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials (RECONNECT). Obstetrics & Gynecology. https://clinicaltrials.gov/study/NCT02333071
- US National Library of Medicine (2026). ClinicalTrials.gov records for GHK-Cu: NCT07437586, phase 2, acute skin wound healing, recruiting, 60 participants; completed registry record a 27-participant phase 4 study of facial skin quality, hydration and barrier function. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07437586
- US National Library of Medicine (2026). PubMed search: glutathione[tiab] AND injected route AND (skin OR detoxification OR fatigue OR energy) AND randomized controlled trial[pt] — 7 records, none testing injected glutathione alone; ClinicalTrials.gov injected-route glutathione — 3 studies. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=glutathione%5Btiab%5D+AND+randomized+controlled+trial%5Bpt%5D
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.